Distinguishing indolent from aggressive prostate cancer

Area of Science:

• Oncology
• Genomics
• Proteomics

Background:

• Prostate cancer exhibits variable clinical behavior, making prognosis difficult with limited information.
• Distinguishing aggressive from indolent tumors requires advanced analytical methods.
• Current diagnostic procedures lack standardization, hindering reliable comparisons.

Purpose of the Study:

• To explore the utility of genomic, proteomic, and biomarker analyses in predicting prostate cancer prognosis.
• To identify potential biomarkers for differentiating between aggressive and indolent prostate tumors.
• To address the challenges posed by prostate cancer heterogeneity and procedural variability.

Main Methods:

• Genomic analysis, including single nucleotide polymorphism (SNP) identification.
• Proteomic studies focusing on protein expression and modifications.
• Biomarker measurement in prostate tissue, serum, and urine.
• Investigating specific markers like Akt phosphorylation and TMPRSS2-ERG fusion.

Main Results:

• Single nucleotide polymorphisms may indicate prostate cancer risk, but prognostic value is uncertain.
• High Akt phosphorylation in tumor tissue suggests a poor prognosis.
• The TMPRSS2-ERG gene fusion, found in 50% of tumors, may promote malignancy.
• Biomarkers detectable in various bodily samples show potential for distinguishing tumor types.

Conclusions:

• Prognostic biomarker development for prostate cancer faces limitations due to tumor heterogeneity.
• Non-standardized genomic and proteomic procedures impede inter-laboratory result comparison.
• Further research and procedural unification are necessary for reliable prostate cancer prognostic tools.